Skip to main content
Equibles

Helen Sabzevari

CEO

Precigen, Inc. (PGEN)

Board Member

Precigen, Inc. (PGEN)

Equibles does not estimate personal net worth.

Get an email with a short summary when Precigen, Inc. publishes a filing, an earnings call transcript or a press release.

Get PGEN alerts

About Helen Sabzevari

Helen Sabzevari is recorded as Board Member at Precigen, Inc. (PGEN) since June 26, 2025 and CEO at Precigen, Inc. (PGEN). The newest filing on record that lists Helen Sabzevari as CEO at Precigen, Inc. (PGEN) is dated April 30, 2026. The proxy statement of Precigen, Inc. reports total compensation of $5,354,329 for Helen Sabzevari in fiscal 2025, including a base salary of $1,000,000. Disclosed compensation is on record for 8 fiscal years. Helen Sabzevari has spoken on 15 earnings calls across 1 company, most recently for Precigen, Inc. on August 4, 2026. Precigen, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Precigen, Inc. includes Helen Sabzevari, Ph.D. (CEO), Randal J. Kirk (Chairman and Board Member), Randal Kirk (Chairman and Board Member) and 7 others.

Helen Sabzevari on recent calls

“Thank you, Steve, and thank you to everyone joining us for our Q2 2026 business update call. As we approach the one-year anniversary of Topsimius approval in August 2025, it is worth reflecting on what a meaningful milestone this has been for adults with RRP.”
CEO, Precigen, Inc. Q2 FY2026 Earnings Call ·
“The approval of Paximius in August of 2025 has brought a novel first-line standard of care treatment for adults with RRP. In nine short months, we have witnessed tremendous progress with the first commercial therapeutic launch in the disease's history.”
CEO, Precigen, Inc. Q1 FY2026 Earnings Call ·
“I would like to extend a warm welcome to all those joining us for our update call today. In the short time since the early and full approval of Pap smear in August, the standard of care first-line treatment for adults has peaked.”
CEO, Precigen, Inc. Q4 FY2025 Earnings Call ·
“And thank you to all those joining us for our third quarterly update call. The approval of Papcemias in August marked a monumental turning point for all those impacted by recurrent respiratory papillomatosis or RRP.”
CEO, Precigen, Inc. Q3 FY2025 Earnings Call ·
“Thank you, Steve, and thank you to all for taking the time to join us for our year end 2024 update. It is indeed a transformative time at Precigen as we are on the verge of commercializing our lead asset, PRGN-2012 in RRP, potentially bringing a treatment to this patient population with high unmet needs.”
CEO, Precigen, Inc. Q4 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Precigen, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Precigen, Inc. (PGEN) $1,000,000 $5,354,329
2024 Precigen, Inc. (PGEN) $1,000,000 $5,431,895
2023 Precigen, Inc. (PGEN) $1,000,000 $3,719,061
2022 Precigen, Inc. (PGEN) $1,000,000 $3,497,622
2021 Precigen, Inc. (PGEN) $1,000,000 $2,516,170
2020 Precigen, Inc. (PGEN) $1,000,000 $20,409,916
2019 Precigen, Inc. (PGEN) $500,000 $1,465,107
2018 Precigen, Inc. (PGEN) $500,000 $2,722,804

Recent activity

Show 3 earlier activities